Federal University of Minas Gerais
ufmg.brLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
149
Active
18
Phase 3
3
Total enrollment
18,227
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| topical placebo rinse | — | — | — | — | — | 1 | |
| topical clonazepam rinse | — | — | — | — | — | 1 | |
| Resomelagon | — | — | — | — | — | 1 | |
| Vivaxin vaccine manufactured by CT Vacinas/Cristália Laboratory | — | — | — | — | — | 1 |
Next readouts
- 2026-03
- 2026-07-01
- 2027-06
Top conditions
- Stroke7
- Periodontitis6
- Obesity5
- Quality of Life5
- Cerebral Palsy4
- Parkinson Disease4
- Infertility4
- Anxiety4
Frequently asked questions about Federal University of Minas Gerais
- How many clinical trials does Federal University of Minas Gerais have on ClinicalTrials.gov?
- Federal University of Minas Gerais is listed as the lead sponsor on 149 clinical trials in ClinicalTrials.gov, 18 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Federal University of Minas Gerais's trials are in Phase 3?
- 3 of Federal University of Minas Gerais's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Federal University of Minas Gerais focus on?
- Federal University of Minas Gerais's most-studied conditions on ClinicalTrials.gov are Stroke, Periodontitis, Obesity, Quality of Life, Cerebral Palsy.
- When are Federal University of Minas Gerais's next clinical trial readouts?
- Federal University of Minas Gerais has 3 upcoming primary-completion readouts tracked here; the soonest is “Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax."”, expected around 2026-03.